Cytotoxicity assays

Rapidly evaluate the cytotoxicity profile of your therapeutic candidates.

ADCC and CDC assays

Benefit from our expertise in cell panel screening, we provide analysis and interpretation of the cytotoxic effects of your candidates in our highly reproducible Complement-Dependent Cytotoxicity (CDC) assays, NK cell Antibody-Dependent and Cell-mediated Cytotoxicity (ADCC) assays.

How do Horizon's ADCC and CDC assays work?

Outline of the steps involved in our ADCC/CDC assay service, with your own therapeutic added alone or in combination, through to assessment of tumor cells by released calcein:

 ADCC/CDC Assay Service

Moving your therapeutic candidates forward:

  • 384-well assay: Automated, robust and highly reproducible high throughput assay for large scale screening
  • Single agents or combinations: Flexible assay design that can be readily customized to fit your project
  • Multiple donors: Highly enriched natural killer cells from multiple donors to address donor-to-donor variability
  • Extensive human tumor cell line collection (>800) to target your cell surface antigen of interest.
  • 10+ years of combination screening experience: Expert data analysis and interpretation using our proprietary Chalice Analyzer software

To find out more about how we could help with your immuno-oncology research, get in contact with our team today.

Contact Us

 ADCC assays  CDC assays

  

 Figure 1. ADCC assays. Anti-CD20 antibody rituximab dose-dependently induces cytotoxicity of NK cells against CD20+ Daudi cells as measured by calcein release. Figure 2. CDC assays. Rituximab dose-dependently induces cytotoxicity against Daudi cells in the presence of human serum as measured by calcein release. 

 

T cell mediated tumor cell lysis assays

Rapidly identify bispecific antibody candidates in high throughput.

Leveraging Horizon’s extensive expertise in high throughput screening, we provide analysis and interpretation of the effects of your antibody candidates in our highly reproducible assays for T cell-mediated tumor cells lysis.

Horizon brings you a suite of relevant immuno-oncology assays for a wide range of projects. We work closely with our clients to tailor these assays to best answer their scientific questions and to maximize the success of their project.

 

How do Horizon’s T cell-mediated tumor cell lysis assays work?

3DDAA17A7E0E4316BFD362A5EF639D63

How can Horizon’s T cell-mediated tumor cell lysis assay move your therapeutic candidates forward?

  • 384-well assay: Automated, robust and highly reproducible high throughput assay for large scale screening
  • Single agents or combinations: Flexible assay design that can be readily customized to fit your project
  • Highly enriched human primary T cells from multiple donors to address donor-to-donor variability
  • Extensive human tumor cell line collection (>800) to target your cell surface antigen of interest
  • 10+ years of combination screening experience: Expert data analysis and interpretation using our proprietary Chalice™ Analyzer software

FDC411239FAB4D08989E9B21E26E34FD

Figure 1. Anti-CD3/CD19 bispecific T cell engager (BiTE) blinatumomab induces the cytotoxicity of CD3+ T cells against Daudi B lymphoblast cells as measured by calcein release. Selective killing by blinatumomab versus control antibodies is observed.

A3646C1D2C8C41F2930C042FFD30EA28

Figure 2. Blinatumomab mediated cell killing against Daudi B lymphoblast cells as measured by calcein release at various E:T ratios. Selective killing by blinatumomab versus control antibodies is observed.

Contact Us



Antibody-dependent cell mediated phagocytosis

Investigate the mechanism of action of your drug candidate - employ another approach.

Horizon can measure antibody-dependent cellular phagocytosis (ADCP), which relies on macrophages to attack and devour tumor cells following antibody binding. ADCP function is important in therapeutic antibody development, especially for biosimilars.

Results available in a variety of readouts.